Literature DB >> 9125261

Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus.

L Mellemkjaer1, V Andersen, M S Linet, G Gridley, R Hoover, J H Olsen.   

Abstract

OBJECTIVE: To investigate whether systemic lupus erythematosus (SLE) is associated with non-Hodgkin's lymphoma or other malignant neoplasms.
METHODS: Data on a cohort of 1,585 patients with SLE from the nationwide Danish Hospital Discharge Register were linked to information in the Danish Cancer Registry to determine the occurrence of cancer during up to 15 years of followup. The expected number of cancers was calculated from accumulated person-years and national cancer incidence rates.
RESULTS: There was a significant excess of non-Hodgkin's lymphoma among the SLE patients, based on 8 cases observed against 1.5 expected (relative risk [RR] 5.2, 95% confidence interval 2.2-10.3). In addition, a significantly increased RR was found for cancer of the lung (RR 1.9; n = 15), the liver (RR 8.0; n = 5), and the vagina/vulva (RR 5.7; n = 3).
CONCLUSION: There seemed to be a positive association between SLE and non-Hodgkin's lymphoma. Other cancers with a possible virus-related etiology, such as liver and vaginal/vulva cancer, were also observed in excess. In addition, there was an indication of an increased risk of lung cancer among patients who were hospitalized for SLE.

Entities:  

Mesh:

Year:  1997        PMID: 9125261     DOI: 10.1002/art.1780400424

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  58 in total

Review 1.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

2.  A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Brenda M Birmann; Ellen T Chang; Donna Spiegelman; Jon C Aster; Shumin M Zhang; Francine Laden
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

3.  Systemic lupus erythematosus and malignancies risk.

Authors:  Song Mao; Hua Shen; Jianhua Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-29       Impact factor: 4.553

Review 4.  [Rheumatic and hemato-/oncological disorders].

Authors:  M A Reuss-Borst
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 5.  Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 6.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

7.  p185, an immunodominant epitope, is an autoantigen mimotope.

Authors:  Sanjeev Kumar; John A Hinks; Joseph Maman; Chelliah T Ravirajan; Laurence H Pearl; David A Isenberg
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 8.  A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.

Authors:  Hou-Bao Huang; Shu-Chuan Jiang; Jie Han; Qing-Shui Cheng; Chang-Bin Dong; Cai-Ming Pan
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

Review 9.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

10.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.